Megace and Sunitinib malate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Megace (megestrol acetate) and Sunitinib malate (sunitinib malate). Common drug interactions include disseminated intravascular coagulation among females and dehydration among males.

The phase IV clinical study analyzes what interactions people have when they take Megace and Sunitinib malate. It is created by eHealthMe based on reports of 71 people who take the same drugs from the FDA, and is updated regularly.

What is Megace?

Megace has active ingredients of megestrol acetate. It is often used in weight loss. eHealthMe is studying from 10,095 Megace users. Check the latest studies of Megace.

What is Sunitinib malate?

Sunitinib malate has active ingredients of sunitinib malate. eHealthMe is studying from 9,160 Sunitinib malate users. Check the latest studies of Sunitinib malate.

On Jul, 12, 2026

71 people who take Megace and Sunitinib malate together, and have interactions are studied.

Megace and Sunitinib malate drug interactions.

What are the common drug interactions of Megace and Sunitinib Malate, by gender? *:

female:

Disseminated intravascular coagulation (systemic activation of blood coagulation)
General physical health deterioration (weak health status)
Nausea (feeling of having an urge to vomit)
Arrhythmia (irregular heartbeat)
Asthenia (weakness)
Blood glucose increased
Cardiac disorder
Claustrophobia (fear of having no escape and being closed in small spaces)
Disturbance in attention
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble)

male:

Dehydration (dryness resulting from the removal of water)
Renal failure acute (rapid kidney dysfunction)
Acute myocardial infarction (acute heart attack)
Blood creatinine increased
Bone disorder
Diverticular perforation (serious gastrointestinal condition in which the intestine's walls are perforated)
Hypomagnesaemia (electrolyte disturbance in which there is an abnormally low level of magnesium in the blood)
Ischaemic stroke (stroke; caused by an interruption in the flow of blood to the brain)
Abscess jaw (tooth abscess or root abscess)
Adrenal adenoma (benign tumour of the glandular type (adenoma) in the adrenal gland)

What are the common drug interactions of Megace and Sunitinib Malate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

Acute myocardial infarction (acute heart attack)
Nausea (feeling of having an urge to vomit)
Pain
Bone disorder
Embolism (obstruction of an artery, typically by a clot of blood or an air bubble)
Injection site discolouration
Injection site induration
Injection site reaction
Injection site swelling
Injection site urticaria (rash of round, red welts on the skin at injection site)

50-59:

Dehydration (dryness resulting from the removal of water)
Hepatotoxicity (chemical-driven liver damage)
Renal failure (kidney dysfunction)
Ascites (accumulation of fluid in the abdominal cavity)
Diarrhoea
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Hepatic necrosis (large portions of liver die off due to severe liver disease)
Pleural effusion (water on the lungs)
Hepatic failure (liver failure)
Death

60+:

Abdominal pain
Cognitive disorder (mental health disorders affects learning, memory, perception, and problem solving)
Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
Pleuritic pain
Death
Confusional state
Diarrhoea
Diverticulitis (digestive disease which involves the formation of pouches (diverticula) within the bowel wall)
Haemoptysis (blood-stained sputum from the bronchi, larynx, trachea, or lungs)
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)

What are the existing conditions these people have? *

Diabetes: 22 people, 30.99%
High Blood Pressure: 19 people, 26.76%
High Blood Cholesterol: 18 people, 25.35%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 16 people, 22.54%
Renal Cell Carcinoma (a kidney cancer): 15 people, 21.13%
Nausea (feeling of having an urge to vomit): 11 people, 15.49%
Prostate Cancer: 11 people, 15.49%
Iron Deficiency: 11 people, 15.49%
Diarrhea: 10 people, 14.08%
Asthma: 9 people, 12.68%

* Approximation only. Some reports may have incomplete information.

Do you take Megace and Sunitinib malate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously